Drugs & Pharmaceuticals

I wrote about the efficacy, mostly the lack thereof, of Tylenol (aka, acetaminophen, paracetamol) back in 2017 using reviews from the highly-regarde

JB: A new report in USA Today is certainly looking for readers. The title clearly reflects this: “Not 'if' but 'when': Antibiotic resistance poses an existential threat for modern medicine”

This is a rare feel-good moment in the antibiotic space.  Shionogi manufactures and markets cefiderocol, a beta-lactam antibiotic that utilizes a clever siderophore strategy to enter and kill multi-resistant Gram-negative pathogens.

"Chemically induced reprogramming to reverse cellular aging" is the title of a paper that recently appeared in the journal Aging.

Over the past several years, the medical community has learned, to its dismay, that we can experience a “twin-demic” of winter infectious diseases – simultaneous COVID-19 and flu outbreaks resulting in intense stresses on healthcare delivery.

In October 2022, I wrote one of the first articles about xylazine (aka "Tranq"), a drug that was being used (especially in Philadelphia) to cut fentanyl, as if w

In the mid-1990s, an evil new practice – the use of drugs to incapacitate women so that they could not resist sexual assaults – became a serious threat to millions of women.

Anyone who has had the sick, masochistic obsession pleasure of reading my stuff over the years knows quite well that I am not a fan of dietary supplements. So much so that in 2015 New York Attorney General Eric T.

Once upon a time in a land far, far away there was a little antibiotic biotech.

A new study released earlier this year adds more evidence to the mountains of evidence that policymakers trying to solve the overdose crisis have been aiming at the wrong target.